Stifel Downgrades Calliditas Therapeutics to Hold, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Annabel Samimy has downgraded Calliditas Therapeutics (NASDAQ:CALT) from Buy to Hold and lowered the price target from $55 to $40.
May 28, 2024 | 5:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Stifel analyst Annabel Samimy downgraded Calliditas Therapeutics from Buy to Hold and reduced the price target from $55 to $40.
The downgrade from Buy to Hold and the significant reduction in the price target from $55 to $40 by a reputable analyst is likely to negatively impact investor sentiment and the short-term stock price of Calliditas Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100